OT Breast Cancer
Featured Articles


Test Spares Extended Endocrine Therapy in Low-Risk ER+ Breast Cancer

A gene test that predicts relapse in women with ER+ early breast cancer can identify patients with low-risk disease who could safely avoid extending their endocrine therapy beyond the standard 5 years, according to study findings reported in a poster session at the 2018 ASCO Annual Meeting (Abstract 516).

Read More


Superior Survival in Conservatively Treated Male Breast Cancer

Men who had breast-conserving therapy (BCT) including radiation for their early breast cancer lived longer than those who had total or partial mastectomy (with or without radiation) in findings from a large retrospective survey of male breast cancer reported at the 2018 ASCO Annual Meeting (Abstract 565).

Read More